CTLA4 and cancer: Furthermore, combination of PS-targeting mAbs with immune checkpoint blockade (anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or anti-PD-1) has now been evaluated in breast and melanoma syngenic models of cancer in immunocompetent mice [122, 123].